A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)

Trial Profile

A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs VRC-CHKVLP059-00-VP (Primary)
  • Indications Chikungunya virus infections
  • Focus Pharmacodynamics
  • Sponsors PaxVax
  • Most Recent Events

    • 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2018 According to PaxVax media release,company expects results in early 2019
    • 25 Apr 2018 According to PaxVax media release,Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top